Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Aisling Capital and OrbiMed Advisors See Value in This Canadian Pharmaceutical Company, Disclosing New Positions

Page 1 of 2

Dennis Purcell’s Aisling Capital and Samuel Isaly’s OrbiMed Advisors have initiated new positions in Cynapsus Therapeutics Inc (NASDAQ:CYNA). In new filings with the U.S. Securities and Exchange Commission, Aisling Capital disclosed owning 921,381 shares of Cynapsus Therapeutics Inc (NASDAQ:CYNA), representing 8.1% of its outstanding common stock. Meanwhile, OrbiMed Advisors, in a separate filing, reported a 9.99% stake in Cynapsus Therapeutics Inc (NASDAQ:CYNA), containing 1.22 million shares of the company. Both stakes are passive by nature.

Samuel Isaly - Orbimed Advisors

 

We don’t just track the latest moves of hedge funds. We are, in fact, more interested in their 13F filings, which we use to determine the top 15 small-cap stocks held by the funds we track. We gather and share this information based on 16 years of research which showed that these 15 most popular small-cap picks have a great potential to outperform the market, beating the S&P 500 Total Return Index by nearly one percentage point per month in backtests, and easily beating the most popular large-cap picks of funds, which nonetheless get the majority of their collective capital. Why pay fees to invest in both the best and worst ideas of a particular hedge fund when you can simply mimic only the very best ideas of the best fund managers on your own? Since the beginning of forward testing in August 2012, the Insider Monkey small-cap strategy has outperformed the market every year, returning 135.3%, nearly 2.5 times greater returns than the S&P 500 during the same period (see more details).

Aisling Capital is an early-stage investment fund with a focus on healthcare. Founded by Dennis Purcell, the fund has about $1.6 billion in assets under management (AUM). Prior to Aisling, Purcell served as managing director of the Life Sciences Investment Banking Group at Chase H&Q for over five years. Purcell also served as managing director in the healthcare group at PaineWebber. In its latest 13F for the March 31 reporting period, Aisling Capital disclosed a public equity portfolio valued at $764.2 million. The fund’s top holdings, in terms of value, were Esperion Therapeutics Inc (NASDAQ:ESPR), Cempra Inc (NASDAQ:CEMP), and Zeltiq Aesthetics Inc (NASDAQ:ZLTQ).

Dennis Purcell
Dennis Purcell
Aisling Capital

New York-based OrbiMed Advisors is a healthcare fund that invests in pharmaceutical and medical device companies in all stages of development. The fund, which has been investing in such healthcare-related private equities since 1993, focuses on healthcare-related opportunities in North America, Europe, India, China, and Israel. The market value of Orbimed’s public equity portfolio totaled $11.71 billion at the end of the first quarter of 2015. Its top holdings consist of Bristol-Myers Squibb Co (NYSE:BMY), Biogen Inc (NASDAQ:BIIB), and Amgen Inc. (NASDAQ:AMGN).

Page 1 of 2
Loading...